World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
111
Citations
50873
World Ranking
5294
National Ranking
2861

Mark J. Ratain publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mark J. Ratain sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 809 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mark J. Ratain D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mark J. Ratain sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 111 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Mark J. Ratain is affiliated with the University of Chicago in the United States. Their research focuses primarily within the field of Medicine, with particular emphasis on Oncology, Economics and Econometrics, Pharmacology, Molecular Biology, and Pulmonary and Respiratory Medicine.

The scientist's work covers a range of topics including Health Systems, Economic Evaluations, Quality of Life; Pharmacogenetics and Drug Metabolism; Colorectal Cancer Treatments and Studies; Economic and Financial Impacts of Cancer; Statistical Methods in Clinical Trials; Cancer Genomics and Diagnostics; and Chronic Lymphocytic Leukemia Research.

Frequent publication venues for their research include:

  • UNC Libraries
  • Clinical Pharmacology & Therapeutics
  • Journal of Clinical Oncology
  • The Journal of Clinical Pharmacology
  • JAMA Oncology

Recent papers authored or co-authored by Mark J. Ratain encompass a variety of clinical and pharmacological themes, such as:

  • "COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia" (2020, Clinical Pharmacology & Therapeutics)
  • "Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value" (2020, Clinical Pharmacology & Therapeutics)
  • "Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments" (2021, Journal of Clinical Oncology)
  • "Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19" (2020, JAMA Oncology)
  • "Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy" (2020, Clinical Pharmacology & Therapeutics)

Co-authors frequently collaborating with Mark J. Ratain include:

  • Garth W. Strohbehn
  • Kouros Owzar
  • Peter H. O'Donnell
  • Keith Danahey
  • Daniel A. Goldstein

The scientist has also been recognized as a member of the Association of American Physicians.

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • Tumour heterogeneity in the clinic

    Philippe L. Bedard;Aaron R. Hansen;Aaron R. Hansen;Mark J. Ratain;Lillian L. Siu;Lillian L. Siu

  • Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

    Federico Innocenti;Samir D. Undevia;Lalitha Iyer;Pei Xian Chen

  • Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

    Lalitha Iyer;Christopher D. King;Peter F. Whitington;Mitchell D. Green

  • UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

    L Iyer;S Das;L Janisch;M Wen

  • Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

    T Eisen;T Ahmad;K T Flaherty;M Gore

  • Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

    Jonas A. de Souza;Bonnie J. Yap;Kristen Wroblewski;Victoria Blinder

  • Perceptions of cancer patients and their physicians involved in phase I trials.

    Christopher Daugherty;Mark J. Ratain;Eugene Grochowski;Carol Stocking

  • Metabolic Fate of Irinotecan in Humans: Correlation of Glucuronidation with Diarrhea

    Elora Gupta;Timothy M. Lestingi;Rosemarie Mick;Jacqueline Ramirez

  • Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

    Razelle Kurzrock;Steven I. Sherman;Douglas W. Ball;Arlene A. Forastiere

  • The development of a financial toxicity patient-reported outcome in cancer: The COST measure.

    Jonas A. de Souza;Bonnie J. Yap;Fay J. Hlubocky;Kristen Wroblewski

  • Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

    Jason J. Luke;Jeffrey M. Lemons;Theodore G. Karrison;Sean P. Pitroda

  • Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

    Lalitha Iyer;Diana Hall;Soma Das;Melissa A. Mortell

  • Oral chemotherapy: rationale and future directions.

    Mark D. DeMario;Mark J. Ratain

  • Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung.

    MJ Ratain;LS Kaminer;JD Bitran;RA Larson

  • Pharmacokinetic variability of anticancer agents

    Samir D. Undevia;Gonzalo Gomez-Abuin;Mark J. Ratain

  • Pharmacogenomics: Challenges and Opportunities

    Dan M. Roden;Russ B. Altman;Neal L. Benowitz;David A. Flockhart

  • Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.

    H M Golomb;A Jacobs;A Fefer;H Ozer

  • The Development of a Financial Toxicity Patient-Reported Outcome in Cancer

    Jonas A. de Souza;Bonnie J. Yap;Fay J. Hlubocky;Kristen Wroblewski

Frequent Co-Authors

Richard L. Schilsky
Richard L. Schilsky University of Chicago
Federico Innocenti
Federico Innocenti University of North Carolina at Chapel Hill
Everett E. Vokes
Everett E. Vokes University of Chicago
Theodore Karrison
Theodore Karrison University of Chicago
Walter M. Stadler
Walter M. Stadler University of Chicago
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Gini F. Fleming
Gini F. Fleming University of Chicago
Rosemarie Mick
Rosemarie Mick University of Pennsylvania
Soma Das
Soma Das University of Chicago
Harvey M. Golomb
Harvey M. Golomb University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine can open doors to a variety of related healthcare fields. For those seeking flexibility and affordability, online programs are an excellent option. Many students start their journey with nursing, exploring what is the cheapest online college for nursing? to help minimize debt while gaining essential qualifications.

As you progress, you may look at advancing your career by becoming a nurse practitioner. Today’s affordable online FNP programs allow working professionals to upskill from home, preparing for more specialized, in-demand roles.

Many registered nurses choose to further their education through the cheapest RN to BSN programs, which expand career options and earning potential. For those passionate about academic research or leadership, online PhD nursing programs offer a pathway to the highest levels in healthcare education and practice.

Exploring these online pathways can help you build a rewarding medical career, tailored to your interests, ambitions, and budget.

Best Scientists Citing Mark J. Ratain

Trending Scientists

Recently Published Articles